Impact of the conjugate pneumococcal vaccine in Arkansas

Pediatric Infectious Disease Journal

Volumn 23, Issue 12, 2004, Pages 1125-1129

  Schutze, Gordon E ^a,b   Tucker, Nancy C ^b   Mason Jr , Edward O ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Conjugate vaccine; Pneumococcus; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE;

AFRICAN AMERICAN; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION; IMMUNOLOGY; NEWBORN;

ARKANSAS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 16644378329     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000145478.36236.1e     Document Type: Article

References (24)

1. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269:221-226.
2. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-1995. MMWR. 1996;45:901-906.
3. Overturf GD, the Committee on Infectious Disease. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000;106:367-376.
4. Committee on Infectious Diseases. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2, pt 1)362-366.
5. Centers for Disease Control and Prevention Advisory Committee On Immunization Practices. Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage. MMWR. 2001;50:1140-1142.
6. Centers for Disease Control and Prevention. Notice to readers: pneumococcal conjugate vaccine shortage resolved. MMWR. 2003;52:446-447.
7. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
8. Kaplan SL, Mason EO Jr, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics. 1998;102:538-545.
9. Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. In: Thirteenth Informational Supplement (Aerobic Dilution). Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
10. Schutze GE, Tucker NC, Mason EO Jr. Failure of the conjugate pneumococcal vaccine to prevent recurrent bacteremia in a child with human immunodeficiency virus disease. Pediatr Infect Dis J. 2001;20: 1009-1010.
11. Centers for Disease Control and Prevention. National Immunization Survey 2003. Available at: http://www.cdc.gov/nip/coverage/default. htm#NIS. Accessed March 5, 2004.
12. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-poly saccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
13. Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason EO Jr. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine. Pediatrics. 2002;111:896-899.
14. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489.
15. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive pneumococcal infections. JAMA. 2004;291:2197-2203.
16. Dagan R, Melamed R, Muallem, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996;174:1271-1278.
17. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927-936.
18. Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet. 2003;361:2189-2195.
19. Finkelstein JA, Huamg SS, Daniel J, et al. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predicators of carriage in a multicommunity sample. Pediatrics. 2003;112:862-869.
20. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis. 1999;180:1569-1576.
21. Väkeväinen M, Eklund C, Eskola J, Käyhty H. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccine in infants. J Infect Dis. 2001;184:789-793.
22. Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun. 2003;71:2956-2959.
23. Byington CL, Spencer LY, Johnson TA, et al. Epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002;34: 434-440.
24. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110:1-6.